Breaking News Instant updates and real-time market news.

BG

Bunge

$59.47

0.84 (1.43%)

, ADM

Archer Daniels

$44.45

-1.08 (-2.37%)

08:16
12/10/18
12/10
08:16
12/10/18
08:16

Bunge may be open to reengaging in talks with ADM, Glencore, Bloomberg reports

Following the departure of CEO Soren Schroder, Bunge (BG) is said to be open to reengaging in talks with Archer-Daniels Midland (ADM) and Glencore (GLNCY), Bloomberg reports, citing a person familiar with the matter. Archer-Daniels and a unit of Glencore held merger talks with Bunge in 2017 and earlier in 2018 without reaching a deal, and while Bunge is not actively seeking new talks, the person says that the fact that it does not plan to appoint a new permanent CEO immediately "creates an opportunity for rivals to re-approach" Bunge. Reference Link

BG

Bunge

$59.47

0.84 (1.43%)

ADM

Archer Daniels

$44.45

-1.08 (-2.37%)

GLNCY

Glencore

$0.00

(0.00%)

BG Bunge
$59.47

0.84 (1.43%)

11/01/18
SBSH
11/01/18
NO CHANGE
Target $82
SBSH
Buy
Citi says Bunge is for sale, sees takeout value at $90 per share
Citi analyst David Driscoll says that with Bunge adding three "new, high quality" members to its board and initiating a strategic review, he believes the company is for sale in whole, or parts. The analyst thinks Bunge possesses medium term earnings power of $7.00 per share, and sees a takeout value of $90 per share. Driscoll lowered his price target for the stock to $82 from $92 and keeps a Buy rating on Bunge.
08/02/18
JPMS
08/02/18
DOWNGRADE
Target $75
JPMS
Neutral
Bunge downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Ann Duignan downgraded Bunge to Neutral and lowered her price target for the shares to $75 from $82.
08/02/18
JPMS
08/02/18
DOWNGRADE
Target $75
JPMS
Neutral
JPMorgan downgrades Bunge on 'high bar' second half guidance
JPMorgan analyst Ann Duignan downgraded Bunge to Neutral from Overweight and lowered her price target for the shares to $75 from $82. Share upside is limited by the "high bar" set for the second half of 2018 and "still elevated execution risks" from uncertain trade policy and unresolved freight challenges in Brazil, Duignan tells investors in a research note after Bunge reiterated its 2018 EBIT guidance. She believes the aforementioned may drive further earnings volatility in 2018 and sees fewer near-term catalysts.
09/25/18
SBSH
09/25/18
NO CHANGE
SBSH
Buy
Citi sees 'significant turnaround' for Bunge, adds to Catalyst Watch list
Citi analyst David Driscoll added Bunge to its Catalyst Watch list ahead of the company's Q3 results. After meeting with CEO Soren Schroder, the analyst believes Bunge is set up for an inflection in Q3. He thinks the company can see "record" earnings in the second half of the year and a "significant turnaround" relative to its poor first half results. Driscoll keeps a Buy rating on the shares.
ADM Archer Daniels
$44.45

-1.08 (-2.37%)

11/08/18
ARGS
11/08/18
UPGRADE
Target $53
ARGS
Buy
Archer Daniels upgraded to Buy from Hold at Argus
Argus analyst Deborah Ciervo upgraded Archer Daniels to Buy with a price target of $53, citing the company's recent strong performance and improvement in its Oilseeds, Origination, and Nutrition divisions. The analyst also raised his FY18 EPS view by 10c to $3.59 and FY19 view by 8c to $3.66 thanks to the impact of its cost savings efforts. Ciervo has a positive view of the company's long-term strategy, which includes "global expansion through acquisitions and joint ventures, the sale of underperforming businesses, and cost-cutting initiatives".
11/08/18
11/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Archer Daniels (ADM) upgraded to Buy from Hold at Argus with analyst Deborah Ciervo citing the company's recent strong performance and improvement in its Oilseeds, Origination, and Nutrition divisions. 2. Ultragenyx (RARE) upgraded to Neutral from Sell at Citi with analyst Yigal Nochomovitz saying his long-standing concerns on Ultragenyx's valuation "have substantially played out with recent pipeline disclosures having rapidly reset the valuation." 3. Medifast (MED) upgraded to Buy from Neutral at Sidoti. 4. Knight-Swift (KNX) upgraded to Buy from Neutral at Goldman Sachs with analyst Matthew Reustle saying he is bullish on Knight citing incremental evidence that the merger with Swift Transportation will deliver margin improvement through the end of the decade, reduced investor expectations following recent estimate revisions, and a view that Knight is more defensive through a down-cycle with a de-risked valuation. 5. Axon (AAXN) Enterprise upgraded to Overweight from Neutral at JPMorgan with analyst Mark Strouse saying the stock pulled back 16% yesterday following the company's Q3 results and guidance that implies a dip in revenue growth during Q4. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/18
SPHN
08/16/18
NO CHANGE
Target $57
SPHN
Overweight
Archer Daniels price target raised to $57 after Brazilian deal at Stephens
Stephens analyst Farha Aslam noted that terms of Archer Daniels' deal to purchase Brazilian assets from Algar Agro were not disclosed, but she estimates the transaction to be valued at $200M-$300M. Aslam, who sees the deal strengthening Archer Daniels' positioning in the key agriculture market of Brazil, raised her price target on the stock to $57 from $52 and keeps an Overweight rating on Archer Daniels shares.
11/08/18
ARGS
11/08/18
UPGRADE
ARGS
Buy
Archer Daniels upgraded to Buy from Hold at Argus
GLNCY Glencore
$0.00

(0.00%)

04/30/18
RBCM
04/30/18
DOWNGRADE
RBCM
Outperform
Glencore downgraded to Outperform at RBC Capital on DRC order freeze
As reported earlier, RBC Capital analyst Tyler Broda downgraded Glencore to Outperform from Top Pick and lowered his price target to GBp 410 from GBp 460. Broda notes continued deterioration the company's Democratic Republic of Congo business after it received freezing orders for its Katanga and Mutanda sites late on Friday via a $3B claim from Dan Gertler for not paying royalties. The analyst expects volatility in the stock to remain high but keeps a generally constructive outlook for the company, adding that uncertainty around DRC was already high while the valuation has brought Glencore shares down to level in line with sector peers.
07/03/18
JEFF
07/03/18
NO CHANGE
JEFF
Jefferies lowers Glencore price target on U.S. subpoena risk
Jefferies analyst Christopher LaFemina lowered his price target for Glencore (GLNCY) shares to 440p from 500p citing higher risk after the company received a subpoena from the U.S. Department of Justice. News of the subpoena increases the geopolitical overhang on Glencore shares, even if there are no charges against the company in the end, LaFemina tells investors in a research note. The analyst keeps a Buy rating on the shares but sees better risk/rewards in other major diversified miners Anglo American (NGLOY) and Rio Tinto (RIO).
09/10/18
JPMS
09/10/18
DOWNGRADE
JPMS
Neutral
Glencore downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Dominic O'Kane downgraded Glencore to Neutral and removed the shares from his firm's European Analyst Focus List. The company's "investment appeal" is unlikely to be reinstated until regulatory risks are resolved, the analyst tells investors in a research note. He lowered his price target for the shares to 370p from 520p.
09/25/18
MSCO
09/25/18
UPGRADE
MSCO
Overweight
Glencore upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Menno Sanderse upgraded Glencore to Overweight while lowering his price target for the shares to EUR 3.90 from EUR 4.0. The analyst views the recent pullback in the Europe metals and mining sector as a buying opportunity.

TODAY'S FREE FLY STORIES

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01
Hot Stocks
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial »

Caladrius Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$6.52

0.1 (1.56%)

12:59
11/17/19
11/17
12:59
11/17/19
12:59
Hot Stocks
Kiniksa presents Rilonacept final Phase 2 clinical data »

Kiniksa Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

12:57
11/17/19
11/17
12:57
11/17/19
12:57
Hot Stocks
The Medicines Co's ORION-10 study of Inclisiran met primary, secondary endpoints »

The Medicines Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

12:54
11/17/19
11/17
12:54
11/17/19
12:54
Hot Stocks
Amgen analysis shows benefit of Repatha in high risk patients »

Amgen announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CNI

Canadian National

$93.64

0.46 (0.49%)

12:52
11/17/19
11/17
12:52
11/17/19
12:52
Hot Stocks
Canadian National receives strike notice from train conductor union »

CN said that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 22

    Nov

ADAP

Adaptimmune

$0.71

-0.0959 (-11.87%)

12:51
11/17/19
11/17
12:51
11/17/19
12:51
Hot Stocks
Adaptimmune data confirms ADP-A2M4 delivers clinical benefit »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$110.02

-0.01 (-0.01%)

, BMY

Bristol-Myers

$58.61

0.11 (0.19%)

12:47
11/17/19
11/17
12:47
11/17/19
12:47
Hot Stocks
Bristol-Myers sees no further extension for Celgene notes due to merger closing »

Bristol-Myers Squibb…

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

ETNB

89bio

$26.03

3.03 (13.17%)

, YAYO

YayYo

$3.65

-0.29 (-7.36%)

11:09
11/17/19
11/17
11:09
11/17/19
11:09
On The Fly
Opening Day: 89bio has strong opening week »

89bio (ETNB) finished its…

ETNB

89bio

$26.03

3.03 (13.17%)

YAYO

YayYo

$3.65

-0.29 (-7.36%)

CAN

Canaan

$0.00

(0.00%)

SITM

SiTime

$0.00

(0.00%)

BABA

Alibaba

$185.44

2.75 (1.51%)

YXR

YX Asset Recovery

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.